Vidofludimus calcium is under clinical development by Immunic and currently in Phase III for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase III drugs for Coronavirus Disease 2019 (COVID-19) have a 13% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Vidofludimus calcium’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vidofludimus calcium overview
Vidofludimus calcium (IMU-838) is under development for the treatment of relapsing-remitting multiple sclerosis, progressive multiple sclerosis and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), primary progressive multiple sclerosis (ppms), secondary progressive multiple sclerosis (spms) and long COVID (post COVID syndrome). The drug candidate is administered by oral route. It is a calcium salt of vidofludimus. It targets dihydroorotate dehydrogenase (DHODH) andNurr1 (Nuclear receptor related 1). It was under development for the treatment of ulcerative colitis, primary sclerosing cholangitis and crohn's disease.
Immunic overview
Immunic (Immunic Therapeutics) is a biopharmaceutical company that discovers, develops and commercializes oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company’s pipeline products include vidofludimus calcium IMU-838, a selective immune modulator for the treatment of relapsing-remitting multiple sclerosis (RRMS), progressive multiple sclerosis and moderate-to-severe ulcerative colitis. Its other pipelines include IMU-856 and IMU-381 for celiac disease, inflammatory bowel disease, short bowel syndrome and irritable bowel syndrome with diarrhea and gastrointestinal diseases. The company operates in Germany and the US. Immunic Therapeutics is headquartered in New York, the US.
For a complete picture of Vidofludimus calcium’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
